The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

scPharmaceuticals Inc. (NASDAQ:SCPH) just released its latest full-year results and things are looking bullish. It looks like a positive result overall, with revenues of US$14m beating forecasts by 2.4%. Statutory losses of US$1.42 per share were 2.4% smaller than the analysts expected, likely helped along by the higher revenues. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

View our latest analysis for scPharmaceuticals

Following the latest results, scPharmaceuticals' six analysts are now forecasting revenues of US$40.1m in 2024. This would be a huge 195% improvement in revenue compared to the last 12 months. The loss per share is expected to ameliorate slightly, reducing to US$1.47. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$38.9m and losses of US$1.22 per share in 2024. So it's pretty clear the analysts have mixed opinions on scPharmaceuticals even after this update; although they upped their revenue numbers, it came at the cost of a massive increase in per-share losses.

There was no major change to the consensus price target of US$19.50, with growing revenues seemingly enough to offset the concern of growing losses. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values scPharmaceuticals at US$25.00 per share, while the most bearish prices it at US$16.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await scPharmaceuticals shareholders.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting scPharmaceuticals' growth to accelerate, with the forecast 195% annualised growth to the end of 2024 ranking favourably alongside historical growth of 101% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 9.0% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that scPharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. The consensus price target held steady at US$19.50, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on scPharmaceuticals. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for scPharmaceuticals going out to 2026, and you can see them free on our platform here..

Plus, you should also learn about the 1 warning sign we've spotted with scPharmaceuticals .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.